Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xeruborbactam
- Development stage
- Phase 1
- Lead developer
- Qpex Biopharma
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Xeruborbactam is a synthetic small molecule, specifically a cyclic boronic acid-based beta-lactamase inhibitor (BLI) with ultra-broad spectrum activity. It inhibits both serine and metallo-beta-lactamases, including class A (KPC), class D (OXA-type), and metallo-beta-lactamases, thereby restoring the efficacy of beta-lactam antibiotics against multidrug-resistant Gram-negative bacteria such as Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa. Xeruborbactam was developed by Qpex Biopharma as a next-generation BLI following vaborbactam to address resistance in serious bacterial infections. It has completed Phase 1 clinical trials for intravenous administration in combination with other beta-lactams and is also being evaluated as an orally bioavailable prodrug (xeruborbactam isoboxil)[1][3][4][8].
- Brand names
- OMNivance
- Other names
- xeruborbactam [INN]
02
Targets
Neuraminidaseβ-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on xeruborbactam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xeruborbactam.